Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
Information source: Shaheed Beheshti Medical University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Neovascular Age-Related Macular Degeneration
Intervention: verteporfin, bevacizumab, triamcinolone acetonide (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Shaheed Beheshti Medical University Official(s) and/or principal investigator(s):
Hamid Ahmadieh, MD, Principal Investigator, Affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
Overall contact:
Hamid Ahmadieh, MD, Phone: +98 21 22585952, Email: hahmadieh@hotmail.com
Summary
To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal
bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and
intravitreal triamcinolone for neovascular AMD.
Clinical Details
Study design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Visual acuity
Secondary outcome: Central macular thicknessLeakage in fluorescein angiography Intraocular pressure Anterior chamber reaction
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Cases of active neovascular AMD with visual acuity of 20/400- 20/40
Exclusion Criteria:
- History of glaucoma or ocular hypertension
- Disciform scar
Locations and Contacts
Hamid Ahmadieh, MD, Phone: +98 21 22585952, Email: hahmadieh@hotmail.com
Hamid Ahmadieh, MD, Tehran 16666, Iran, Islamic Republic of; Recruiting
Hamid Ahmadieh, MD, Phone: +98 21 22585952, Email: hahmadieh@hotmail.com
Additional Information
Starting date: September 2006
Ending date: November 2006
Last updated: November 13, 2006
|
